$1.09
+0.19 (+21.10%)
Open$0.93
Previous Close$0.90
Day High$1.10
Day Low$0.90
52W High$2.98
52W Low$0.56
Volume—
Avg Volume5.51M
Market Cap93.07M
P/E Ratio—
EPS$-1.70
SectorBiotechnology
Analyst Ratings
Buy
8 analysts
Price Target
+1,699.1% upside
Current
$1.09
$1.09
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 195.1K | 1.05M | 29.02M |
| Net Income | -252,412,390 | -1,225,964,117 | -227,719 |
| Profit Margin | -130,006.0% | -123,505.7% | -0.8% |
| EBITDA | -253,777,760 | -1,301,073,243 | -290,155 |
| Free Cash Flow | — | — | -255,634 |
| Rev Growth | -81.5% | -81.5% | +16.9% |
| Debt/Equity | — | — | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |